43 completed, 10 terminated, 9 recruiting, 5 unknown. 74 Phase 1, 23 Phase 2.
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies BL-M24D1 - Multiple Myeloma, Hematologic Malignancies | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 33 | 2026-03-25 | 2026-06-04 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies INCA036873 - Solid Tumors, Hematologic Malignancies | Phase 1 | Recruiting | Incyte Corporation | 280 | 2026-01-08 | 2026-10-09 |
| A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies 19UCART injection - Hematologic Malignancies, Lymphoma | Phase 1 | Not yet recruiting | YANRU WANG | 12 | 2025-12-22 | 2026-01-05 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 155 | 2025-11-14 | 2026-10-16 |
| This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile. RJK-RT2831 dose-escalation phase Ia, RJK-RT2831 Dose Expansion Phase Ib - Hematologic Malignancies | Phase 1 | Recruiting | Nanjing RegeneCore Biotech Co., Ltd. | 71 | 2025-03-25 | 2026-01-30 |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer IM-1021 - Solid Malignancies, Hematologic Malignancies | Phase 1 | Recruiting | Immunome, Inc. | 190 | 2025-02-26 | 2026-08-10 |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies KQB198, Dasatinib - Hematologic Malignancies, Adult | Phase 1 | Active not recruiting | Kumquat Biosciences Inc. | 13 | 2024-12-09 | 2026-03-25 |
| Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant Cyclophosphamide - Hematologic Malignancies | Phase 1 | Recruiting | Ronald Paquette | 26 | 2023-10-24 | 2026-08-05 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-11-09 |
| Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment Pralatrexate Injection - Advanced Solid Tumors, Hematologic Malignancies | Phase 1 | Recruiting | Acrotech Biopharma Inc. | 24 | 2022-12-28 | 2026-02-11 |
| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy GNC-035 - Hematologic Malignancies | Phase 1 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 33 | 2022-02-09 | 2025-09-26 |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies CN202 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Unknown | Curon Biopharmaceutical (Australia) Co Pty Ltd | 164 | 2021-10-22 | 2021-08-31 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma Teclistamab - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Janssen Pharmaceutical K.K. | 40 | 2021-02-22 | 2026-06-05 |
| RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies RD13-01 cell infusion - Hematologic Malignancies | Phase 1 | Completed | He Huang | 12 | 2020-09-10 | 2022-01-25 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors AZD0466 - Advanced Solid Tumors, Lymphoma | Phase 1 | Terminated | AstraZeneca | 9 | 2019-12-16 | 2023-08-02 |
| Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan - Hematologic Malignancies | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2019-09-18 | 2026-10-23 |
| A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies Venetoclax, ethinyl estradiol/levonorgestrel - Hematologic Malignancies | Phase 1 | Unknown | AbbVie | 12 | 2019-07-30 | 2024-08-29 |
| GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease Itacitinib, Calcineurin inhibitor - Hematologic Malignancies | Phase 1 | Terminated | Incyte Corporation | 84 | 2018-02-27 | 2025-10-21 |
Showing 20 of 74. Sign in to see all of them.
Hematologic Neoplasms (74) · Lymphoma (12) · Leukemia (10) · Lymphoma, Non-Hodgkin (10) · Neoplasms (10) · Hodgkin Disease (9) · Multiple Myeloma (9) · Leukemia, Myeloid, Acute (8) · Graft vs Host Disease (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Myelodysplastic Syndromes (7) · Recurrence (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Anemia, Refractory, with Excess of Blasts (3)
Hemic and Lymphatic Diseases (74) · Neoplasms by Site (74) · Hematologic Diseases (73) · Neoplasms (64) · Immune System Diseases (31) · Neoplasms by Histologic Type (31) · Immunoproliferative Disorders (25) · Lymphoproliferative Disorders (25) · Lymphatic Diseases (23) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Disease Attributes (16) · Bone Marrow Diseases (13) · Leukemia (12) · Leukemia, Myeloid (12)
fludarabine (10) · Tacrolimus (9) · Cyclophosphamide (5) · Melphalan (5) · Mycophenolic Acid (5) · Whole-Body Irradiation (5) · fludarabine phosphate (5) · Sirolimus (4) · venetoclax (4) · Antilymphocyte Serum (3) · Busulfan (3) · Hematopoietic Stem Cell Transplantation (3) · Thiotepa (3) · Alemtuzumab (2) · Azacitidine (2)
Amgen (3) · Fate Therapeutics (3) · M.D. Anderson Cancer Center (3) · Millennium Pharmaceuticals, Inc. (3) · National Cancer Institute (NCI) (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · AbbVie (2) · Dana-Farber Cancer Institute (2) · Incyte Corporation (2) · Kiromic BioPharma Inc. (2) · Pfizer (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · A.O. Ospedale Papa Giovanni XXIII (1) · Abramson Cancer Center at Penn Medicine (1)
United States (57) · France (9) · Italy (7) · China (6) · Spain (6) · Australia (4) · Germany (4) · Netherlands (4) · United Kingdom (4) · Canada (3) · Belgium (2) · Denmark (2) · Japan (2) · Norway (1) · Poland (1)
Neal Flomenberg, MD (2) · Alessandro Rambaldi, MD (1) · Attaphol Pawarode, M.D. (1) · Boon Cher Goh, M.D. (1) · Brandon Triplett, MD (1) · Charles Chuah, M.D. (1) · Chen Yu, MD (1) · Chris Storgard, MD (1) · Christopher G Kanakry, M.D. (1) · Christopher J Melani, M.D. (1)
PMID 16732175, PMID 18468541, PMID 18703664, PMID 18820709, PMID 19713456, PMID 20350611, PMID 21393326, PMID 21417678, PMID 21868572, PMID 22491731, PMID 23190221, PMID 23993427, PMID 23996087, PMID 24295572, PMID 25075128, PMID 25428504, PMID 26688487, PMID 26755520, PMID 27354021, PMID 28017967, PMID 28601972, PMID 29026685, PMID 29191916, PMID 29233821, PMID 29242852, PMID 29423515, PMID 30073642, PMID 30077125, PMID 30219915, PMID 30242306, PMID 30962222, PMID 31135970, PMID 31204078, PMID 31355467, PMID 31358540, PMID 31542806, PMID 31647026, PMID 32586767, PMID 33241650, PMID 33451977, PMID 33568344, PMID 33993815, PMID 34425261, PMID 34699069, PMID 35467243, PMID 36151216, PMID 36720090, PMID 36841672, PMID 37354069, PMID 37882668
2009 (1), 2016 (1), 2017 (1), 2025 (1), P01CA015396 (1)